Gene therapy

Arabindra B. Katwal, Brian H. Annex

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD). Clinical symptoms of CLI include rest pain, ischemic lesions/ulcers, and/or gangrene. Patients with CLI frequently end up having amputation and are at a very high risk of cardiovascular events, including death. Revascularization with angioplasty or bypass is the current standard of care for CLI. However, the treatment options for patients who are unsuitable for or fail revascularization attempts are extremely limited. Therapeutic angiogenesis is a novel strategy in the management of CLI. While the preclinical studies and phase I/II trials of therapeutic angiogenesis using gene and molecular-based therapies in patients with CLI showed promising results, outcomes of recent larger phase II/III studies have been inconsistent. However, as our understanding of the complex cellular and genetic mechanisms underlying angiogenesis, the experience with novel vectors and genetic targets, and preclinical and clinical trial design continue to get refined, the promise of therapeutic angiogenesis with gene therapy for CLI remains strong.

Original languageEnglish (US)
Title of host publicationEndovascular Interventions
Subtitle of host publicationA Case-Based Approach
PublisherSpringer New York
Pages1257-1265
Number of pages9
ISBN (Electronic)9781461473121
ISBN (Print)9781461473114
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Genetic Therapy
Ischemia
Extremities
Therapeutics
Genetic Vectors
Gangrene
Peripheral Arterial Disease
Standard of Care
Amputation
Angioplasty
Ulcer
Clinical Trials
Pain
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Katwal, A. B., & Annex, B. H. (2014). Gene therapy. In Endovascular Interventions: A Case-Based Approach (pp. 1257-1265). Springer New York. https://doi.org/10.1007/978-1-4614-7312-1_105

Gene therapy. / Katwal, Arabindra B.; Annex, Brian H.

Endovascular Interventions: A Case-Based Approach. Springer New York, 2014. p. 1257-1265.

Research output: Chapter in Book/Report/Conference proceedingChapter

Katwal, AB & Annex, BH 2014, Gene therapy. in Endovascular Interventions: A Case-Based Approach. Springer New York, pp. 1257-1265. https://doi.org/10.1007/978-1-4614-7312-1_105
Katwal, Arabindra B. ; Annex, Brian H. / Gene therapy. Endovascular Interventions: A Case-Based Approach. Springer New York, 2014. pp. 1257-1265
@inbook{2e274aa5a3134343bf85a22c67e27b94,
title = "Gene therapy",
abstract = "Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD). Clinical symptoms of CLI include rest pain, ischemic lesions/ulcers, and/or gangrene. Patients with CLI frequently end up having amputation and are at a very high risk of cardiovascular events, including death. Revascularization with angioplasty or bypass is the current standard of care for CLI. However, the treatment options for patients who are unsuitable for or fail revascularization attempts are extremely limited. Therapeutic angiogenesis is a novel strategy in the management of CLI. While the preclinical studies and phase I/II trials of therapeutic angiogenesis using gene and molecular-based therapies in patients with CLI showed promising results, outcomes of recent larger phase II/III studies have been inconsistent. However, as our understanding of the complex cellular and genetic mechanisms underlying angiogenesis, the experience with novel vectors and genetic targets, and preclinical and clinical trial design continue to get refined, the promise of therapeutic angiogenesis with gene therapy for CLI remains strong.",
author = "Katwal, {Arabindra B.} and Annex, {Brian H.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-7312-1_105",
language = "English (US)",
isbn = "9781461473114",
pages = "1257--1265",
booktitle = "Endovascular Interventions",
publisher = "Springer New York",

}

TY - CHAP

T1 - Gene therapy

AU - Katwal, Arabindra B.

AU - Annex, Brian H.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD). Clinical symptoms of CLI include rest pain, ischemic lesions/ulcers, and/or gangrene. Patients with CLI frequently end up having amputation and are at a very high risk of cardiovascular events, including death. Revascularization with angioplasty or bypass is the current standard of care for CLI. However, the treatment options for patients who are unsuitable for or fail revascularization attempts are extremely limited. Therapeutic angiogenesis is a novel strategy in the management of CLI. While the preclinical studies and phase I/II trials of therapeutic angiogenesis using gene and molecular-based therapies in patients with CLI showed promising results, outcomes of recent larger phase II/III studies have been inconsistent. However, as our understanding of the complex cellular and genetic mechanisms underlying angiogenesis, the experience with novel vectors and genetic targets, and preclinical and clinical trial design continue to get refined, the promise of therapeutic angiogenesis with gene therapy for CLI remains strong.

AB - Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD). Clinical symptoms of CLI include rest pain, ischemic lesions/ulcers, and/or gangrene. Patients with CLI frequently end up having amputation and are at a very high risk of cardiovascular events, including death. Revascularization with angioplasty or bypass is the current standard of care for CLI. However, the treatment options for patients who are unsuitable for or fail revascularization attempts are extremely limited. Therapeutic angiogenesis is a novel strategy in the management of CLI. While the preclinical studies and phase I/II trials of therapeutic angiogenesis using gene and molecular-based therapies in patients with CLI showed promising results, outcomes of recent larger phase II/III studies have been inconsistent. However, as our understanding of the complex cellular and genetic mechanisms underlying angiogenesis, the experience with novel vectors and genetic targets, and preclinical and clinical trial design continue to get refined, the promise of therapeutic angiogenesis with gene therapy for CLI remains strong.

UR - http://www.scopus.com/inward/record.url?scp=84956615869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956615869&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-7312-1_105

DO - 10.1007/978-1-4614-7312-1_105

M3 - Chapter

AN - SCOPUS:84956615869

SN - 9781461473114

SP - 1257

EP - 1265

BT - Endovascular Interventions

PB - Springer New York

ER -